Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience. [electronic resource]
Producer: 20210614Description: e209-e216 p. digitalISSN:- 1938-0682
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- B7-H1 Antigen -- antagonists & inhibitors
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Prognosis
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Response Evaluation Criteria in Solid Tumors
- Retrospective Studies
- Survival Rate
- Urologic Neoplasms -- drug therapy
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.